COLL - NASDAQ
Collegium Pharmaceutical, Inc.
$31.06
+1.9%Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; and Xtampza ER for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
At a Glance
Live SnapshotCollegium Pharmaceutical, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Healthy operating margins demonstrate effective cost control and strong business fundamentals.
Net Profit Margin
Moderate profitability with room for improvement. Monitor interest expenses and tax efficiency.
Effective Tax Rate
Higher tax burden may reflect limited tax optimization or operations in high-tax jurisdictions.
Profitability Insight
High margin compression: Large gap between gross and net margins suggests operational inefficiencies or heavy debt burden. Focus on expense management and deleveraging.
Collegium Pharmaceutical, Inc. Income Statement
COLL • NASDAQ
| Collegium Pharmaceutical, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | |||||||||||||
780.6M | 631.4M | 566.8M | 463.9M | 276.9M | 310M | 296.7M | 280.4M | 28.5M | 1.7M | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | |||||||||||||
(317.3M) | (254.1M) | (240.6M) | (254.4M) | (126.3M) | (130.2M) | (193.7M) | (165.7M) | (2.6M) | (213K) | (171K) | (0.0) | (0.0) | |
463.3M | 377.3M | 326.2M | 209.5M | 150.6M | 179.8M | 103M | 114.7M | 25.9M | 1.5M | -171K | 0.0 | 0.0 | |
OPERATING INCOME | |||||||||||||
(276.2M) | (207.4M) | (159.2M) | (176.2M) | (133M) | (123.6M) | (126.8M) | (135.4M) | (101.3M) | (95.6M) | (26.9M) | (17.7M) | (16M) | |
(276.2M) | (183M) | (159.2M) | (172.2M) | (119M) | (113.8M) | (116.4M) | (126.8M) | (92.8M) | (80.6M) | (18.9M) | (2.7M) | (1.9M) | |
(0.0) | (0.0) | (0.0) | (4M) | (9.5M) | (9.8M) | (10.3M) | (8.7M) | (8.6M) | (14.9M) | (8M) | (15M) | (14.2M) | |
187.1M | 169.9M | 167M | 33.3M | 17.6M | 56.2M | -23.7M | -20.7M | -75.4M | -94.1M | -26.9M | -17.7M | -16M | |
PRE-TAX INCOME | |||||||||||||
(82.3M) | (74M) | (83.3M) | (63.2M) | (21M) | (28.9M) | (909K) | (20.1M) | (0.0) | (94K) | (439K) | (252K) | (76K) | |
-71M | -60M | -67.7M | -62.2M | -21M | -28.7M | 1M | -18.4M | 582K | -94K | 0.0 | 0.0 | 0.0 | |
(0.0) | (24.5M) | (0.0) | (0.0) | (4.6M) | (0.0) | (0.0) | (0.0) | (0.0) | -94K | (0.0) | (0.0) | (0.0) | |
-94.5M | -71.3M | -91.2M | -62.2M | -21M | -28.7M | 1M | -18.4M | 582K | -94K | -348K | -252K | -155K | |
92.6M | 98.6M | 75.7M | -28.8M | -3.4M | 27.6M | -22.7M | -39.1M | -74.9M | -94.2M | -27.3M | -17.9M | -16.2M | |
NET INCOME | |||||||||||||
(29.7M) | (29.4M) | (27.6M) | -3.8M | -74.9M | (830K) | (0.0) | (0.0) | (0.0) | (94K) | -91K | (0.0) | (79K) | |
62.9M | 69.2M | 48.2M | -25M | 71.5M | 26.8M | -22.7M | -39.1M | -74.9M | -94.2M | -27.3M | -17.9M | -16.2M |
SEC Filings
COLL - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 15, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 07, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 07, 2026 | May 07, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 07, 2026 | May 14, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 02, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 19, 2026 | March 19, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 26, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 26, 2026 | February 26, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 08, 2026 | 2026 |
Related Guides
Continue your COLL research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.